A Cohort Study Of End Point Events In Patients With Myocardial Infarction Treated By Compound Danshen Dripping Pills

ObjectiveA follow-up study was performed in patients with myocardial infarction,to understand the occurrence of Compound Danshen dripping pills and end point events in patients after discharge of the situation,to explore the relationship between the incidence and related factors of using compound Danshen dripping pills after discharge and end point events,impact assessment of Compound Danshen Dripping Pills on myocardial infarction in patients with long-term prognosis.MethodsUsing retrospective cohort study design definition of compound danshen dropping pill as the exposure group,28 days or in shandong province eight 3 armour hospital patients with acute myocardial infarction(mi),and its follow-up after discharge the usage of compound danshen dropping pill and end events happening,using analysis of variance,method such as chi-square analysis data,and USES the multi-factor logistic regression analysis of compound danshen dropping pill and its related factors and end point event correlation.Results1.The result of follow-up:1452 patients with myocardial infarction(mi)in this study,complete the follow-up of 1210 cases,242 cases can't get in touch or not the author,lost to follow-up rate was 16.7%,followed up for 6 months to 6 years and 9 months,the average(32.4 ± 17.8)months.2.The usage of compound danshen dropping pill: exposure group(using the compound danshen dropping pill 28 days or higher)in 207 cases,non exposed group 993 cases,of which exposed group(using the compound danshen dropping pill for six months or more)of 72 cases in the exposed group(using the compound danshen dropping pill and < 3 months or 6 months),64 cases,weak exposure group and 28 days(using the compound danshen dropping pill acuity < 3 months)in 71 cases.3.The end point event : the end of the event during the follow-up period of cardiovascular readmission(27.60%),cardiac death(14.05%),recurrence of myocardial infarction(7.85%),acute heart failure(8.34%),reascularization(5.70%),severe arrhythmia(4.38%).4.Chi-square test results: the incidence of cardiac death in each exposed group and the incidence of recurrent myocardial infarction were significantly different from that of non-exposed groups(P<0.05).4.Logistic regression analysis results: exposure(OR = 0.313,95% CI = 0.119 0.897),strong exposure(OR = 0.140,95% CI = 0.042 0.468)is a protective factor of cardiac death,antithrombotic drugs is readmission(OR = 0.524,95% CI = 0.364 0.753)and recurrence of myocardial infarction(OR = 0.524,95% CI = 0.364 0.753)of the protection factors.Age is a cardiac death(OR = 1.073,95% CI = 1.054 1.093),acute heart failure(OR = 1.073,95% CI = 1.048 1.099)risk factors,combined with type 2 diabetes is a cardiac death(OR = 2.247,95% CI = 1.601 3.153),acute heart failure(OR = 2.032,95% CI = 1.335 3.092)of the risk factors.ConclusionCompound Danshen dripping pills can reduce the risk of cardiac death and re infarction in patients with myocardial infarction during follow-up period.The use of Compound Danshen dripping pills for more than 6 months of myocardial infarction is more beneficial.